...
首页> 外文期刊>Stem cells translational medicine. >Noninvasive Assessment of an Engineered Bioactive Graft in Myocardial Infarction: Impact on Cardiac Function and Scar Healing
【24h】

Noninvasive Assessment of an Engineered Bioactive Graft in Myocardial Infarction: Impact on Cardiac Function and Scar Healing

机译:工程性生物活性移植物在心肌梗死中的非侵入性评估:对心脏功能和疤痕愈合的影响

获取原文
           

摘要

Cardiac tissue engineering, which combines cells and biomaterials, is promising for limiting the sequelae of myocardial infarction (MI). We assessed myocardial function and scar evolution after implanting an engineered bioactive impedance graft (EBIG) in a swine MI model. The EBIG comprises a scaffold of decellularized human pericardium, green fluorescent protein‐labeled porcine adipose tissue‐derived progenitor cells (pATPCs), and a customized‐design electrical impedance spectroscopy (EIS) monitoring system. Cardiac function was evaluated noninvasively by using magnetic resonance imaging (MRI). Scar healing was evaluated by using the EIS system within the implanted graft. Additionally, infarct size, fibrosis, and inflammation were explored by histopathology. Upon sacrifice 1 month after the intervention, MRI detected a significant improvement in left ventricular ejection fraction (7.5% ± 4.9% vs. 1.4% ± 3.7%; p = .038) and stroke volume (11.5 ± 5.9 ml vs. 3 ± 4.5 ml; p = .019) in EBIG‐treated animals. Noninvasive EIS data analysis showed differences in both impedance magnitude ratio (?0.02 ± 0.04 per day vs. ?0.48 ± 0.07 per day; p = .002) and phase angle slope (?0.18° ± 0.24° per day vs. ?3.52° ± 0.84° per day; p = .004) in EBIG compared with control animals. Moreover, in EBIG‐treated animals, the infarct size was 48% smaller (3.4% ± 0.6% vs. 6.5% ± 1%; p = .015), less inflammation was found by means of CD25+ lymphocytes (0.65 ± 0.12 vs. 1.26 ± 0.2; p = .006), and a lower collagen I/III ratio was detected (0.49 ± 0.06 vs. 1.66 ± 0.5; p = .019). An EBIG composed of acellular pericardium refilled with pATPCs significantly reduced infarct size and improved cardiac function in a preclinical model of MI. Noninvasive EIS monitoring was useful for tracking differential scar healing in EBIG‐treated animals, which was confirmed by less inflammation and altered collagen deposit. S tem C ells T ranslational M edicine 2017;6:647–655
机译:结合细胞和生物材料的心脏组织工程有望限制心肌梗塞(MI)的后遗症。在猪MI模型中植入工程化的生物活性阻抗移植物(EBIG)后,我们评估了心肌功能和疤痕的演变。 EBIG包括一个脱细胞的人心包支架,绿色荧光蛋白标记的猪脂肪组织来源的祖细胞(pATPC),以及定制设计的电阻抗光谱(EIS)监测系统。通过使用磁共振成像(MRI)来无创地评估心脏功能。通过在植入的移植物中使用EIS系统评估疤痕的愈合。另外,通过组织病理学研究了梗塞的大小,纤维化和炎症。干预后1个月处死后,MRI检查发现左心室射血分数(7.5%±4.9%比1.4%±3.7%; p = .038)和中风量(11.5±5.9 ml vs. 3±4.5)有明显改善。 ml; p = .019)。无创EIS数据分析显示出阻抗幅值比(每天0.02±0.04与每天0.48±0.07; p = 0.002)和相角斜率(每天0.18°±0.24°与3.52°之间)都有差异与对照组动物相比,EBIG每天±0.84°; p = .004)。此外,在接受EBIG治疗的动物中,梗死面积缩小了48%(3.4%±0.6%比6.5%±1%; p = .015),通过CD25 + 淋巴细胞(0.65±0.12 vs. 1.26±0.2; p = .006),并且检测到较低的胶原蛋白I / III比(0.49±0.06 vs. 1.66±0.5; p = .019)。在MI的临床前模型中,由充满pATPC的无细胞心包膜组成的EBIG可显着减少梗塞面积并改善心功能。无创EIS监测可用于追踪EBIG治疗动物的差异性疤痕愈合,这可通过减少炎症和改变胶原沉积来证实。系统杂志翻译医学杂志,2017年; 6:647–655

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号